|
Worldwide Autoinjectors Industry to 2035 - Featuring AbbVie, Bayer and Biocorp Among Others
Thursday, December 16, 2021
DUBLIN, Dec. 16, 2021 /PRNewswire/ -- The "Global Autoinjectors Market by Type of Autoinjector, Route of Administration, Type of Molecule, Therapeutic Indication and Geography: Industry Trends and Global Forecasts, 2021-2035" report has been added to ResearchAndMarkets.com's offering.
http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
This report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of autoinjectors till 2035. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.
According to the National Health Interview Survey (NHIS), nearly 52% of the adult population in the US is diagnosed with at least one chronic condition, such as asthma, diabetes, and hypertension. The annual cost burden associated with chronic disorders in the US is around USD 3.7 trillion; this accounts for nearly 20% of the country's GDP share.
A major share of expenses incurred by patients living with a chronic disorder is driven by the frequent need to medicate, which may require repeated visits to hospitals/out-patient clinics. In addition, patient compliance and adherence to the treatment regimen prove to be a challenge. In order to mitigate this challenge, a wide variety of self-administering injectable drugs have been developed, which impart greater independence and psychological benefits to the patients, as compared to drug administration by healthcare professionals.
Amongst the various self-injection devices, autoinjectors have steadily gained prominence, especially for the treatment of emergency and chronic conditions, such as anaphylactic shock and rheumatoid arthritis. The additional features of autoinjectors, such as integrated needle safety, Bluetooth connectivity, and monitoring injection dose history, enable them to resolve several injection-related compliance issues faced by the patients.
Given the inherent benefits of autoinjectors, a number of players have launched their proprietary products in combination with autoinjectors for use across a wide array of disease indications. One of the most widely recognized autoinjector in the market is EpiPen (Mylan), which is a prefilled epinephrine autoinjector. The generic version of EpiPen received the FDA approval in 2018. Notable examples of other autoinjector-based combination products include Fasenra Pen (AstraZeneca), Gvoke Hypopen (Xeris Pharmaceuticals), NUCALA Autoinjector (GlaxoSmithKline), and VyleesiT Autoinjector (AMAG Pharmaceuticals/Palatin Technologies).
Apart from being a patient-friendly alternative to conventional drug delivery methods, autoinjectors also serve as potential life cycle management tools; several pharmaceutical players have reformulated their proprietary drugs as autoinjector combination products to expand market exclusivity period. For instance, Amgen reformulated lyophilized Enbrel for delivery via the SureClick autoinjector to extend the patent protection of the drug by almost 11 years.
Further, it is worth mentioning that several autoinjector developers have made significant efforts in developing novel autoinjector technologies, paving the way for new generation of autoinjector devices. The field is presently witnessing several innovations, such as LED/LCD-based visualization, Bluetooth connectivity, dosage recording, safety lock, visual/audible drug delivery confirmation notifications, and automatic drug reconstitution. In this context, it is worth highlighting that nearly 5,000 patents have been filed/granted, since 2015, for autoinjectors and affiliated products/technologies. We believe that such efforts are likely to drive growth in this market over the coming years.
In addition to other elements, the study includes:
-- An overview of the current market landscape of autoinjectors that are
either marketed/being developed by various stakeholders, providing
information on the usability (disposable and reusable), type of primary
drug container (cartridge, syringe and vial), volume of container, type
of dose (fixed and variable), route of administration (intradermal,
intracavernosal, intramuscular and subcutaneous), actuation mechanism
(automatic and manual) and feedback mechanism integrated in the device.
It also provides details on the developers, highlighting their year of
establishment, company size (small, mid-sized, large and very large),
and location of headquarters.
-- A competitiveness analysis of various disposable and reusable
autoinjectors, taking into consideration supplier power of their
developers (based on year of establishment and company size) and key
product specifications, such as route of administration, primary drug
container used, injector actuation mechanism, type of dose and user
friendliness of the product.
-- A detailed brand positioning analysis of leading industry players
(shortlisted on the basis of strength of product portfolio),
highlighting the current perceptions regarding their proprietary brands
by taking into consideration several relevant aspects, such as strength
and diversity of product portfolio, route of administration, actuation
mechanism, geographical presence/reach and supplier power of each
company.
-- An in-depth analysis of the patents that have been filed/granted for
autoinjectors, highlighting trends across key parameters, such as type
of patent, publication year, issuing authority, CPC classification,
emerging focus areas and leading industry players (on the basis of
number of patents). It also includes a detailed patent benchmarking and
an insightful valuation analysis.
-- A review of autoinjectors being developed in combination with drugs,
featuring details on initial year of approval (for marketed products),
phase of development, usability of the device, route of administration
(intracavernous, intramuscular and subcutaneous), type of drug molecule
(antibody, peptide, protein and small molecule), dose strength,
therapeutic area and other approved dosage forms (for marketed
products). In addition, the chapter provides details on the developers,
including year of establishment, company size and location of
headquarters.
-- Detailed case studies on the most commonly targeted indications,
covering history of development and detailed description of the approved
autoinjector products, along with their respective mechanisms of action
and historical sales records. The study also includes a list of the
drugs that are currently being delivered via autoinjectors.
-- A list of marketed drugs/therapies and pipeline candidates that are
likely to be developed in combination with autoinjectors in the near
future, shortlisted on the basis of an in-depth analysis that takes into
consideration various relevant parameters, such as route of
administration, type of drug molecule, target indications, other
available dosage forms (for approved drugs) and historical annual sales
information (for approved drugs).
-- Elaborate profiles of autoinjector manufacturers that have more than
three devices in their respective product portfolios; each profile
features an overview of the company, its financial information (if
available), information on its product portfolio, autoinjector device
specifications, collaborations, recent developments and an informed
future outlook. Additionally, the report includes brief profiles of
emerging players that have been established in the past decade.
-- A list of key opinion leaders (KOLs) within this domain who were
short-listed based on their contributions (such as involvement in
clinical trials and research publications); it features a schematic
world map representation, highlighting the geographical locations of
eminent scientists/researchers engaged in this domain.
-- An analysis of the recent collaborations (since 2016) focused on the
development of autoinjectors. It includes partnerships inked by various
stakeholders in this domain, covering licensing agreements (specific to
technology platforms and product candidates), product development and
commercialization agreements, mergers and acquisitions, and other
relevant agreements.
-- A SWOT analysis capturing the key parameters and trends that are likely
to influence the future of autoinjectors market.
-- A case study on the role of CMOs offering services for drug delivery
devices; it features a list of service providers, highlighting the
various types of services offered for different types of drug-delivery
devices.
-- An overview of the current market landscape of companies engaged in
manufacturing prefilled syringes, providing information on year of
establishment, company size, geographical location of the headquarters
and manufacturing facilities, type of material used (glass and plastic),
number of barrel chambers (single chamber and dual chamber), type of
needle system (fixed needle system, luer lock and luer cone) and syringe
volume.
Key Questions Answered
-- Who are the leading autoinjector device developers?
-- For which disease indications are autoinjector-based combination
products available?
-- Which partnership models are commonly adopted by stakeholders developing
autoinjectors?
-- Which drug candidates are likely to be considered for administration via
autoinjectors?
-- How has the intellectual property landscape of autoinjectors evolved
over the years?
-- Who are the Key Opinion Leaders across different regions of the world?
-- Who are the leading contract manufacturing organizations providing
services for autoinjector devices?
-- What is the share of autoinjector devices, in terms of revenue
generation potential, across different disease markets?
-- How is the current and future opportunity likely to be distributed
across key market segments?
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. PRIMARY DRUG CONTAINERS
5. AUTOINJECTORS: CURRENT MARKET LANDSCAPE
6. PRODUCT COMPETITIVENESS ANALYSIS
7. BRAND POSITIONING ANALYSIS OF KEY INDUSTRY PLAYERS
8. PATENT ANALYSIS
9. THERAPEUTIC PRODUCTS AVAILABLE IN AUTOINJECTORS
10. CASE STUDY: AUTOINJECTOR-BASED COMBINATION PRODUCTS AND AFFILIATED THERAPEUTIC AREAS
11. LIKELY DRUG CANDIDATES FOR DELIVERY VIA AUTOINJECTORS
12. COMPANY PROFILES
13. EMERGING PLAYERS
14. KEY OPINION LEADERS (KOL) ANALYSIS
15. PARTNERSHIPS AND COLLABORATIONS
16. SWOT ANALYSIS
17. CASE STUDY: MEDICAL DEVICE CONTRACT SERVICE PROVIDERS
18. CASE STUDY: PREFILLED SYRINGES
19. MARKET SIZING AND OPPORTUNITY ANALYSIS
20. EXECUTIVE INSIGHTS
21. CONCLUDING REMARKS
22. APPENDIX 1: TABULATED DATA
23. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Companies Mentioned
-- AbbVie
-- Aktiv Pharma Group
-- ALK-Abello
-- Allergy Therapeutics
-- Alvogen
-- Alvotech
-- AMAG Pharmaceuticals
-- Amgen
-- Amneal Pharmaceuticals
-- Amphastar Pharmaceuticals
-- Androsystems
-- Antares Pharma
-- Aptar
-- Asahi Kasei Pharma
-- Ascendis Pharma
-- AstraZeneca
-- Battelle
-- Bayer
-- Becton Dickinson
-- Bespak (acquired by Recipharm)
-- Biocorp
-- Biogen
-- BioGene Pharmaceutical
-- Boehringer Ingelheim
-- Bristol-Myers Squibb
-- Cambridge Consultants
-- Celltrion
-- ChemProtect.SK
-- Chugai Pharmaceutical
-- CinnaGen
-- Creare
-- Crossject
-- DALI Medical Devices
-- Dr. Reddy's Laboratories
-- Duoject Medical Systems
-- Elcam Medical
-- Eli Lilly
-- EMD Serono
-- Eton Pharmaceuticals
-- F. Hoffmann-La Roche
-- Ferring Pharmaceuticals
-- Fresenius Kabi
-- Fujifilm Kyowa Kirin Biologics
-- Genentech (subsidiary of Roche)
-- GlaxoSmithKline
-- Grand Pharma
-- Idorsia Pharmaceuticals
-- Impax Pharmaceuticals (subsidiary of Amneal Pharmaceuticals)
-- Jabil
-- Janssen Biotech
-- Janssen Research and Development
-- JCR Pharmaceuticals
-- Jiangsu Delfu medical device
-- Kaleo
-- King Pharmaceuticals (acquired by Pfizer)
-- LG Chem
-- Lincoln Medical (acquired by Bioprojet Pharma)
-- Lineage Cell Therapeutics
-- Lunatus Medical Company
-- Medexus Pharmaceuticals
-- Medicom Innovation Partner (acquired by Phillips-Medisize)
-- Merck
-- Meridian Medical Technologies
-- Midas Pharma
-- MiniEpi
-- Momenta Pharmaceuticals
-- Mylan
-- Nemera
-- Neuma
-- Nipro
-- Novartis
-- Ology Bioservices (subsidiary of National Resilience)
-- Oval Medical Technologies (acquired by SMC)
-- Owen Mumford
-- PA Consulting Group
-- Palatin Technologies
-- Pfizer
-- PharmaConsult
-- Phillips-Medisize (acquired by Molex)
-- Promius Pharma (subsidiary of Dr. Reddy's Laboratories)
-- Rafa Laboratories
-- RAVIMED
-- Regeneron Pharmaceuticals
-- Rx Bandz
-- Samsung Bioepis
-- Sandoz
-- Sanofi
-- Shire (subsidiary of Takeda Pharmaceutical)
-- SHL Medical
-- Stevanato Group
-- Sumitomo Dainippon Pharma
-- Sun Pharmaceutical Industries
-- Survival Technologies
-- Symatese
-- Takeda Pharmaceutical Company
-- Teva Pharmaceutical Industries
-- UCB Biopharma
-- Union Medico
-- US WorldMeds
-- Bausch Health Companies (formerly Valeant Pharmaceuticals International)
-- Weibel CDS (subsidiary of SHL Medical)
-- Weiss-Aug
-- West Pharmaceutical Services
-- Windgap Medical
-- Xeris Pharmaceuticals
-- Ypsomed
-- Zion Clinical Pharmacy
For more information about this report visit https://www.researchandmarkets.com/r/l2o4sm
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:https://www.prnewswire.com/news-releases/worldwide-autoinjectors-industry-to-2035---featuring-abbvie-bayer-and-biocorp-among-others-301446589.html
SOURCE Research and Markets
|
|
|
|
|
|
 |
Skunk Works® and XTEND Expand Joint All Domain Command and Control for Advanced Mission Execution | Jan 22, 2026
|
|
Sup AI Sets New Benchmark Record with 52.15% on Humanity's Last Exam | Jan 22, 2026
|
|
Weekly Recap: 11 Tech Press Releases You Need to See | Jan 22, 2026
|
|
Trigent Partners with WeWork India to Expand its GCC Footprint | Jan 22, 2026
|
|
DEADLINE ANNOUNCED FOR 2026 NEW TOP-LEVEL DOMAIN APPLICATIONS | Jan 22, 2026
|
|
Exia Labs Brings Keystone to the U.S. Navy via DIU's Blue Object Management Challenge | Jan 22, 2026
|
|
Genpact Named a Leader in ISG Provider Lens(TM) 2025 for Insurance GCCs and Agentic AI Services | Jan 22, 2026
|
|
Marketing Evolution Announces New Investment Led by Insight Partners to Power AI-Ready Marketing Data for the Agentic Era | Jan 22, 2026
|
|
Glasswall Brings Defense-Level File Sanitization to Every Government Agency and Business Using Microsoft 365 | Jan 22, 2026
|
|
Altair HyperWorks 2026 Delivers Design and Simulation at Scale with AI | Jan 22, 2026
|
|
|
|
